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Head and neck cancer (HNC), affecting the oral cavity, 
pharynx, and larynx, are the eighth most prevalent cancer 
type in the world.1 Radiotherapy is a mainstay of treat-
ment administered to more than two-thirds of HNC 
patients.2 Nevertheless, they often encounter a common 
and debilitating complication characterized by pain and 
erythema or ulceration of the oral mucosa due to altered 
inflammatory response, namely radiation-induced oral 
mucositis (RIOM).3 Research showed that severe RIOM 
may lead to swallowing impairment that impacts nutri-
tional intake and treatment noncompliance, thus leading to 
placement of feeding tubes and hospitalization.4 Faced 
with these dire adverse effects, it is important to seek out 
appropriate treatments that could lessen the likelihood of 
RIOM or reduce its severity.
To date, no definite intervention has been identified to 
efficiently prevent RIOM incidence. Though some support-
ive modalities, included improving oral hygiene, eliminat-
ing local irritants, and frequent rinsing with combination 
therapies have been noted; all of these appeared to merely 
reduce either the discomfort or the severity of symptoms 
after RIOM onset.5,6 However, based on the assertion that 
prevention is preferable to mitigation, efforts should be 
made to identify active interventions which could reduce 
the risk of RIOM and minimize its associated morbidity 
after diagnosis of HNC.
As of now, Chinese herbal medicines have recently 
attracted global attention due to the reliable therapeutic 
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Abstract
Background: Subjects with head and neck cancer (HNC) often experience post-treatment side effects, particularly 
radiation-induced oral mucositis (RIOM). This study aimed to explore the association of Chinese herbal medicine use with 
the sequent risk of RIOM among them. Methods: This cohort study used a nationwide health insurance database to identify 
subjects newly diagnosed with HNC, aged 20 to 60 years, who received treatment between 2000 and 2007. Among them, 
a total of 561 cases received CHM after HNC onset (CHM users); the remaining 2395 cases were non-CHM users. All 
patients were followed to the end of 2012 to identify any treatment for RIOM as the end point. Cox proportional hazards 
regression was used to compute the adjusted hazard ratio (aHR) of RIOM by CHM use. Results: During the follow-up 
period, 183 CHM users and 989 non-CHM users developed RIOM at incidence rates of 40.98 and 57.91 per 1000 person-
years, respectively. CHM users had a lower RIOM risk than the non-CHM users (aHR: 0.68; 95% Confidence Interval: 
0.58-0.80). The most potent effect was observed in those taking CHM for more than 1 year. Use of Baizhi, Danshen, Shao-
Yao-Gan-Cao-Tang, Gan-Lu-Yin, Huangqin, Shu-Jing-Huo-Xue-Tang, and Xin-Yi-Qing-Fei-Tang, was significantly related to 
a lower risk of RIOM. Conclusion: Findings of this study indicated that adding CHM to conventional clinical care could be 
helpful in protecting those with HNC against the onset of RIOM. Further clinical and mechanistic studies are warranted.
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efficacy toward chronic diseases, especially in managing 
the symptoms associated with RIOM.7 A herbal formula, 
Hangeshashinto, was found to be related to the reduced 
infiltration of neutrophils and ofcyclooxygenase-2 in irradi-
ated mucosa, alleviating the discomfort caused by RIOM.8,9 
Also worth noting is the fact that previous reports usually 
are based on relatively small samples of patients, thus 
threatening findings’ representativeness.7 This paucity of 
data may be an obstacle to facilitating treatment and prog-
nosis in such cases. Accordingly, this study aimed to assess 
the association over time of CHM use with the onset of 




For this study, we used a publicly-released cohort dataset 
from the Longitudinal Health Insurance Database (LHID) 
in Taiwan. The LHID is a sub-dataset of the National 
Health Insurance (NHI) program made up of 1 million ran-
domly sampled patients from 1996 to 2012. Constructed 
using a multistage stratified systematic sampling method, 
it is a representative sample, on both sex and age, of these 
1 million insured individuals and of the general population 
of Taiwan.10,11 This cohort database includes (i) personal 
information; (ii) health insurance claims data; (iii) diagnos-
tic codes; (iv) prescription drugs registry; (v) socioeco-
nomic data; and (vi) medical examination information on 
persons covered under the NHI program. This study was 
conducted in accordance with the Helsinki Declaration, 
and was approved by the local institutional review board 
and ethics committee of Buddhist Dalin Tzu Chi Hospital 
(No. B10004021-2).
Study Participants and Variables
We identified patients with HNC using the corresponding 
code in the International Classification of Disease, Ninth 
Revision, Clinical Modification (ICD-9-CM) in the diagnosis 
field. We selected patients 20 to 60 years old with newly diag-
nosed HNC and treated with radiotherapy only between 2000 
and 2007 (ICD-9-CM codes: 140, 141, 143-148, and 161). To 
ensure the identification of HNC patients, only those patients 
who also had a Catastrophic Illness Certification (CIC) due to 
HNC were included in the study. In Taiwan, insured citizens 
with a major disease (eg, schizophrenia, mood disorders, 
immune disease, and cancer) can obtain free care for their ill-
ness, or related medical conditions, during the certificate’s 
validity period. We counted the index date for HNC as the 
date on which the patient gained CIC approval. In order to 
confirm that all enrolled HNC subjects in this study were inci-
dent cases, only new-onset HNC cases were included 
(n = 3651). Among them, a total of 402 patients diagnosed 
with RIOM before the date of HNC onset were excluded. The 
diagnostic algorithm to determine RIOM required at least 3 
outpatient visits, or at least 1 inpatient claim for the ICD-
9-CM codes of 528.01 during the study period. We also 
excluded those with missing data and those who were not fol-
lowed for a minimum of 1 year after HNC diagnosis (n = 293). 
After this filtering process, a total of 2956 new-onset HNC 
cases were selected for further analysis (Figure 1).
We then utilized the frequency of visits to Chinese medi-
cine physicians to verify the CHM exposure of each 
enrollee, because only certified Chinese medicine physi-
cians are allowed to prescribe CHM in Taiwan. Based on 
former methods, CHM users were identified as those who 
had received CHM to treat HNC for more than 30 days, 
whereas those treated for 30 days or less were considered to 
be non-CHM users.12-14 In this study, for the CHM user 
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3651 patients aged 20-60 years old with newly 
diagnosed HNSCC between 2000 and 2007
Subject excluded:
i. 402 patients affected by mucositis before the date of 
HNSCC onset
ii. 293 cases with missing data in the baseline 
characteristics and those follow-up for less than 1 year 
561 were CHM users 2395 were non-CHM
users
183 patients with RIOM 989 patients with RIOM
Figure 1. Flowchart of selection and follow-up of study subjects.
group, the time period between the date of HNC diagnosis 
and the date of first CHM use after HNC represented the 
immortal time, thus inducing an overestimation of the inter-
vention’s beneficial effect. To reduce this bias, we calcu-
lated person-years (PYs) starting from the initiation of 
CHM usage to correct for immortal time for subjects who 
received CHM.15 Therefore, the index date of the follow-up 
period for HNC subjects, classified as non-CHM users, was 
assigned to the date of the first HNC diagnosis, whereas the 
index date of the follow-up period for CHM users was 
assigned to the first date of the initiation of CHM prescrip-
tion. The end date of follow-up period for both groups was 
assigned as the date of the earliest of the following: a diag-
nosis of RIOM, the date of withdrawal from the insurance 
program, or the date of December 31, 2012.
Covariate Assessment
Sociodemographic variables in this study included age, 
gender, income (for estimating insurance payments), and 
urbanization level of the individual’s residential area. 
Monthly income was clarified by the individual insurable 
wage and separated into 3 groups, which contained New 
Taiwan Dollars (NTD) ≤ 17 880, NTD = 17 881 to 43 900, 
and NTD ≥ 43 901. Urbanization levels were divided into 
urban (levels 1-2), suburban (levels 3-4), and rural (levels 
5-7) areas. Level 1 refers to the “most urbanized” communi-
ties and level 7 refers to the “least urbanized” communities.16 
Baseline comorbidities for each enrollee were assigned using 
the established Charlson-Deyo Comorbidity Index (CCI),17 
and based on the individual’s medical records 1 year prior to 
initial entry into the cohort. To avoid double counting and 
possible over-adjustment in the regression model, HNC was 
excluded from the CCI score.
Data Analysis
Categorical variables were reported as percentages, and con-
tinuous variables presented as mean values and their stan-
dard deviations (SD). An independent t-test and a Chi-square 
test were used, as appropriate. To assess the independent 
influence of CHM use on the risk of RIOM, we conducted a 
Cox proportional hazards regression analysis to calculate the 
hazard ratio (HR) after adjusting simultaneously for age, 
insurance premium, urbanization level, and CCI. To further 
clarify the relation between CHM use and RIOM risk, we 
separated the CHM users into those who used CHM for 31 
to 365 days and those who used CHM for >365 days. The 
Kaplan-Meier method was then employed to plot the cumu-
lative incidence of RIOM for each cohort during the follow-
up period, and the log-rank test was performed to assess the 
differences between the 2 curves. Finally, plot values for the 
log(−log[survival]) versus the log of survival time were 
inspected to verify the proportional hazards assumption. All 
analyses were conducted using SAS software version 9.3 
(SAS Institute Inc., Cary, NC, USA). Differences of P < .05 
were determined to be statistically significant.
Results
We identified 2956 patients with HNC during the period 
from 2000 to 2007. Of these, 561 received CHM treatment 
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Figure 2. Cumulative incidence of RIOM among HNC patients with and without CHM use.
and 2395 were non-CHM users. Table 1 shows the demo-
graphic and clinical characteristics of the 2 groups. 
Compared to the non-CHM users, CHM users were more 
likely to be male, younger, and have higher CCI scores (all 
P < .01).
Among all enrollees, 1172 first episodes of RIOM 
occurred, 183 in CHM users and 989 in non-CHM users, 
during follow-up periods of 4465.69 and 17 078.67 PYs, 
respectively. The incidence rate of RIOM was lower among 
CHM users than among non-CHM users (40.98 vs 57.91, 
respectively, per 1000 PYs), with an adjusted HR of 0.68 
(95% Confidence Interval [CI]: 0.58-0.80; Table 2). Of 
note, use of CHM for more than 1 year was associated with 
a 36% decreased risk of RIOM (95% CI: 0.49-0.85). The 
Kaplan-Meier analysis of survival by days of CHM use 
revealed a significantly difference in the survival rate free 
from RIOM across the three groups (P < 0.01).
Table 3 presents the results from this analysis stratified 
by age and gender. Multivariable stratified analysis verified 
that the benefit of CHM therapy in treating RIOM was more 
predominant in females than in males, with an adjusted HR 
of 0.65 (95% CI: 0.53-0.78; Table 3). Additionally, a more 
significant beneficial effect of CHM use was observed 
among younger subjects (adjusted HR: 0.55; 95% CI: 0.44-
0.68). The 10 most commonly prescribed herbal formulae 
for those with HNC are summarized in Table 4. Among 
them, 4 were single-herb products and the rest were multi-
ple-herb products. Cox proportional hazards regression 
analysis showed that the use of Baizhi, Danshen, Shao-Yao-
Gan-Cao-Tang, Gan-Lu-Yin, Huangqin, Shu-Jing-Huo-
Xue-Tang, and Xin-Yi-Qing-Fei-Tang was significantly 
associated with lower risk of RIOM (Table 4).
Discussion
RIOM is the inflammation of the oral mucosa which pres-
ents clinically as edema, erythema, bleeding, ulceration, or 
pain. Given that the adverse side effect of RIOM may 
influence subsequent antineoplastic treatment, it is of great 
significance to prevent or treat RIOM when managing 
HNC patients. This is the first evidence-based cohort study 
determining whether the integration of CHM into the 
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Table 1. Demographic Data and Selected Comorbidities of Study Subjects.
Variables
Non-CHM users CHM users
P-valuen = 2395 (%) n = 561 (%)
Age (y) <.001
 ≤50 1073 (44.8) 316 (56.3)  
 >50 1322 (55.2) 245 (43.7)  
 Mean (SD) 53.24±13.43 47.79 ± 12.81 <.001
Gender <.001
 Female 413 (17.2) 219 (39.0)  
 Male 1982 (82.8) 342 (61.0)  
Monthly income .13
 Low 964 (40.3) 213 (38.0)  
 Median 1309 (54.7) 308 (54.9)  
 High 122 (5.1) 40 (7.1)  
Residential area .07
 Urban 1301 (54.3) 331 (59.0)  
 Suburban 420 (17.5) 99 (17.6)  
 Rural 674 (28.1) 131 (23.4)  
CCI
 Mean (SD) 4.00 (7.01) 5.50 (10.14) <.001
Abbreviations: CHMs, Chinese herbal medicines; SD, standard deviation; CCI, Charlson-Deyo comorbidity index.
Table 2. Risk of RIOM for HNC Subjects Receiving or Not Receiving CHM Use.
Patient group Event PYs Incidence Crude HR (95% CI) Adjusted HR* (95% CI)
Non-CHM users 989 17078.67 57.91 1 1
CHM users 183 4465.69 40.98 0.69 (0.59-0.80) 0.68 (0.58-0.80)
CHM use within 30-365 days 126 2933.43 42.95 0.72 (0.59-0.86) 0.70 (0.58-0.85)
CHM use for more than 365 days 57 1532.26 37.20 0.63 (0.49-0.84) 0.64 (0.49-0.85)
Abbreviations: CHMs, Chinese herbal medicines; PYs, per 1000 person-years; HR, hazard ratio; CI: confidence interval.
*Model adjusted for age, gender, urbanization level, monthly income, and CCI scores.
Table 3. Incidence and Risk of RIOM for HNC Patients Receiving or Not Receiving CHM in the Stratification of Sex and Age.
Variables
Non-CHM users CHM users
Crude HR (95% 
CI)
Adjusted HR (95% 
CI)Case PYs Incidence Case PYs Incidence
Gender
 Female 840 13674.22 61.43 114 2626.07 43.41 0.69 (0.56-0.83) 0.65* (0.53-0.78)
 Male 149 3404.45 43.77 69 1839.62 37.51 0.83 (0.63-1.10) 0.81* (0.67-1.09)
Age
 ≤50 y 465 7530.08 61.75 89 2663.44 33.42 0.57 (0.47-0.72) 0.55** (0.44-0.68)
 >50 y 524 9548.6 54.88 94 1802.25 52.16 0.98 (0.69-1.09) 0.97** (0.66-1.09)
Abbreviations: CHMs, Chinese herbal medicines; PYs, person-years; HR, hazard ratio; CI, confidence interval.
*Model adjusted for age, urbanization level, monthly income, and CCI scores.
**Model adjusted for gender, urbanization level, monthly income, and CCI scores.
conventional therapy could reduce the risk of RIOM in 
HNC patients using a large nationwide claims-based data-
base. Over a 10-year follow-up study, we discovered that 
HNC patients receiving CHM had a lower likelihood of 
RIOM than those not receiving CHM. Furthermore, those 
using CHM treatment for more than 1 year were found to 
have a markedly lower risk of RIOM by nearly 40%. As 
demonstration of a dose-response relationship is consid-
ered strong evidence for a causal relationship between 
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CHM to conventional treatment may help lower RIOM 
risk. While related studies on this topic are scarce, this 
positive therapeutic effect adds to a growing body of litera-
ture on the clinical efficacy of CHM use among HNC 
patients.7
Findings from this study indicated that younger patients 
benefited more from CHM treatment in lowering the risk of 
RIOM, irrespective of other factors. This result may be due 
to younger people having fewer coexisting medical condi-
tions, having better medical knowledge, having a more 
positive attitude toward their medical condition, or having 
more psychosocial and coping resources to rely upon than 
older patients.18 These findings also suggest that younger 
HNC survivors may more easily adapt to the side effects of 
treatment, and consequently are at reduced risk of RIOM. 
Furthermore, the reduction in risk of RIOM was higher for 
females than for males (35% vs 19%). We speculate that 
women may have better health literacy, more willingness to 
adhere to strict medical procedures, and more positive atti-
tudes about self-care than men,19 and accordingly, they 
were more likely to comply with the prescribed medical 
regimen to lower risk of RIOM.
Oral mucositis is any inflammatory mucosal destruction 
presenting as erythema or ulceration of oral mucosa owing 
to the use of chemotherapy or radiation therapy to treat 
cancer.3,6,20 Of the 10 most commonly prescribed herbal 
formulae for HNC patients, we found that 7 were associ-
ated with a significantly lower risk of RIOM. For example, 
the use of Xin-Yi-Qing-Fei-Tang was found to lessen the 
risk of RIOM by 41%. We speculate that the major ingredi-
ent, Anemarrhena asphodeloides, might produce an appre-
ciable anti-inflammatory effect by abating nuclear factor 
kappa beta (NF-κB) signaling.21 NF-κB is well known as a 
crucial transcription mediator regulating the induction of 
the inflammatory response.22 Xin-Yi-Qing-Fei-Tang also 
showed an effect against a variety of bacteria,23,24 thus min-
imizing the risk of bacterial colonization after ulceration 
develops.
Use of Shu-Jing-Huo-Xue-Tang and Shao-Yao-Gan-
Cao-Tang were also associated with a lower susceptibility 
to developing RIOM. Priori studies in a rodent model 
showed that both compounds can significantly modulate 
the activity of the alpha-2 adrenoceptor (α2-AR).25,26 
Dysregulation of the α2-AR pathway may contribute to the 
release of inflammatory cytokines, such as tumor necrosis 
factor-α (TNF-α), interleukin-1 (IL-1), and IL-6; all of 
these mediators have been implicated in the development 
of RIOM.6,27
Consistent with the findings of earlier research,14,28 this 
study revealed that Gan-Lu-Yin was the most frequently 
used Chinese herbal formula for treating HNC. The posi-
tive association between Gan-Lu-Yin use and a lower inci-
dence of RIOM may stem from its reported effects that 
included reducing cell proliferation and the inhibition of 
inflammatory cytokines through the NF-kB dependent 
pathway.29,30 In 1 previous report, relative to untreated 
controls, rats fed with Gan-Lu-Yin had markedly reduced 
levels of inflammatory markers.30 The inhibition of angio-
genesis may prevent the expression and survival of cancer 
cells, thereby decreasing the risk of RIOM after HNC 
onset.
With regard to the single-herb products used to treat those 
with HNC, we noted that Baizhi was associated with a 
reduced risk of RIOM events. Recently, several laboratory-
identified, anti-inflammatory, properties of Baizhi have been 
reported, including antioxidation,31 anti-inflammatory,32 and 
anti-tumor properties.33 Imperatorin, a candidate compound 
purified from this CHM product, has been proven to pro-
foundly reduce the release of TNF-α, IL-1β, and IL-6 in 
lipopolysaccharide-stimulated RAW 264.7 cells via the sup-
pression of NF-κB activation.32 Additionally, 1 in vitro study 
revealed that imperatorin could mediate oncogene expres-
sion to induce cell cycle arrest.33
The remaining herbal products suggested as effective in 
lessening RIOM risk were Danshen and Huangqin. The 
first belongs to the Campanulaceae family, and its ingredi-
ent was discovered to possess antioxidant, anti-tumor, 
anti-microbial, and immune-boosting properties.34 As for 
Huangqin, Wogonin, its main ingredient, has shown anti-
neoplastic and anti-inflammatory effects in both in vitro 
and in vivo studies. For example, 1 study demonstrated that 
Wogonin can induce AMP-activated protein kinase to 
inhibit proliferation and induce apoptosis in cancer cells.35 
Wogonin was also found beneficial in suppressing the pro-
duction of inflammatory mediators by modulating the 
NF-κB and NF-E2-related factor 2 signaling pathways.36 
These findings may explain the mechanisms responsible 
for the potent effects of Danshen and Huangqin observed 
in this study.
While our study is the first to investigate the relationship 
between CHM use and RIOM risk among patients with 
HNC, there are several important limitations. First, using 
secondary health care databases always entails the risk of 
errors in the coding process. To minimize this bias, we 
enrolled only patients with new-onset HNC or RIOM, and 
only after the patients had at least 3 outpatient visits or 1 
inpatient admission for HNC. Additionally, HNC cases 
were further linked to the CIC database to verify their status 
as patients with a catastrophic disease. It should also be 
noted that the NHI of Taiwan randomly reviews the charts 
and audits medical charges to verify the accuracy of claims 
files. Moreover, the coding approach and data availability 
were similar for the 2 groups, so that any misclassification 
bias would have likely been nondifferential. Second, the 
LHID lacks information on social network relationships, 
smoking, alcohol intake, personality attributes, laboratory 
data, and education level. Thus, future research examining 
these untested variables is needed to better determine the 
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generalizability of our findings. Nevertheless, to thoroughly 
address the confounding by indication that may arise in this 
real-world comparative effectiveness study, we attempted 
to reanalyze the association of CHM use with the risk of 
RIOM via a propensity score – matched analysis. For each 
HNC patient who received CHM, 1 control patient was 
selected by 1:1 matching, based on a propensity score. The 
propensity score was calculated using logistic regression on 
the basis of patients’ demographics and baseline comorbidi-
ties at enrollment. The results of the reanalysis showed that 
no significant difference occurred between the 2 groups 
with regard to age, sex, monthly income, residential area, 
and number of comorbidities after matching procedure with 
propensity score, indicating that the 2 groups were compa-
rable on these characteristics (Supplemental Table 1). 
Furthermore, the use of CHM was still found to be signifi-
cantly related to reduction risk of RIOM among HNC partici-
pants, with the adjusted HR of 0.65 (Supplemental Table 2). 
Third, information regarding dose-limiting toxicity was not 
available in this database, and failure to adjust for this factor 
might bias the results. To address this issue, a sensitivity 
analysis was performed to more carefully examine the 
abovementioned association. First, we applied the numbers 
of radiotherapy utilization after HNC onset to serve as a 
surrogate of dose-limiting toxicities stemming from the 
radiation therapy. After considering this variable, in the 
multivariate analysis, the results indicated that, as com-
pared to HNC patients without CHM use, the selected 
HNC patients with CHM use, still had a significantly lower 
risk for RIOM (adjusted HR: 0.70; 95% CI = 0.59-0.82). 
Therefore, it can be inferred that the level of dose-limiting 
toxicities did not appreciably impact the relationship 
reported herein. Fourth, although the findings of this obser-
vational cohort study conveyed that the continuous use of 
CHM may be beneficial, it must be recognized that partici-
pants were not initially randomly categorized into users and 
nonusers. Therefore, well-designed randomized controlled 
trials are still needed to minimize confounding by covariates 
not explicitly accounted for by the present design, thus pav-
ing the way for further in vivo studies regarding the effects 
of CHM products on patients with other chronic medical 
conditions. These limitations notwithstanding, this study 
also possessed several strengths. One strength of this nation-
wide register-based study is the completeness of the records 
of hospital diagnoses and prescription claims; the minimal 
risk of selection bias and loss to follow-up; and the large 
population of both men and women, which provide suffi-
cient power to conduct detailed analyses.
Conclusion
In summary, this large-scale nationwide cohort study 
showed that, during treatment for HNC, the integration of 
CHM appears to reduce the risk of RIOM by 33%. This 
finding can provide a reference for healthcare providers 
seeking therapeutic interventions to improve the prognosis 
for HNC patients.
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